Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01281488 · ClinicalTrials.gov registry record · Phase 1
Fluorescence Imaging in Finding Tumors in Patients With Kidney Tumors
A Phase 1 study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT01281488 is a Phase 1 study that has completed, run by City of Hope Medical Center. The registered enrollment target is 28 participants.
The verdict
NCT01281488, a Phase 1 study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
RATIONALE: Using fluorescence imaging may determine the extent of kidney tumors and help in planning surgery. PURPOSE: This phase I trial is studying the best way to give indocyanine green (ICG) fluorescence imaging in finding tumors in patients with kidney tumors
Interventions
- PROCEDURE laparoscopic surgery
- PROCEDURE fluorescence imaging
- DRUG indocyanine green
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2011-10-20 |
| Est. Completion | 2017-10-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01281488
The ClinicalTrials.gov registry entry for NCT01281488 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laparoscopic surgery is the first listed.
NCT01281488 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01281488 about?
NCT01281488 is a clinical study titled "Fluorescence Imaging in Finding Tumors in Patients With Kidney Tumors". RATIONALE: Using fluorescence imaging may determine the extent of kidney tumors and help in planning surgery. PURPOSE: This phase I trial is studying the best way to give indocyanine green (ICG) fluorescence imaging in finding tumors in patients with kidney tumors
What is the current status of trial NCT01281488?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2011-10-20. Estimated completion is 2017-10-09.
What interventions are being tested in trial NCT01281488?
The interventions under investigation include: laparoscopic surgery (PROCEDURE), fluorescence imaging (PROCEDURE), indocyanine green (DRUG).
Who is sponsoring clinical trial NCT01281488?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.